News
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones
Jaguar Health, Inc. secures new patent expanding international IP for crofelemer in pediatric intestinal failure disorders, highlighting reductions in parenteral support. Supporting business development plans -
-
-
COMMUNIQUÉ DE PRESSE
In Support of Possible Expedited Approval Pathway for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID), Jaguar Health Submits Amended Protocol to FDA for Ongoing Placebo-Controlled Clinical Trial
Jaguar Health submits amended protocol to FDA for crofelemer in pediatric MVID patients to potentially extend lives and reduce parenteral support by up to 37% -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue
Jaguar Health, Inc. reports proof-of-concept trial shows crofelemer potential for MVID patients, financial results revealed, FDA meeting outcome, and upcoming investor webcast -
